Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using patents to thwart competition.

The saga began early last year when Regeneron filed a lawsuit accusing Amgen of infringing a key patent on its best-selling Eylea injectable drug, which is used to combat such eye diseases as wet ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Options Coach’s Substack by Taylor Selden. In this ...

Patent Analytics Global Market Report 2025 The Business Research Company's Patent Analytics Global Market Report 2025 – Market Size, Trends ...

AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...

Jeffrey E. Gershenwald Consulting or Advisory Role: Merck, Novartis, Syndax, Bristol Myers Squibb, Novartis, Novartis, Regeneron Patents, Royalties, Other Intellectual Property: mercator therapeutics, ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my updated look at MRK and VRNA stock.